预约演示
更新于：2026-06-24
Cixutumumab
西妥木单抗
更新于：2026-06-24
概要
基本信息
原研机构 |
权益机构- |
最高研发阶段临床2期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
结构/序列
Sequence Code 193839L
来源: *****
Sequence Code 201122H
来源: *****
关联
51
项与 西妥木单抗 相关的临床试验JPRN-jRCT1060260033
Effects of Providing Genetic Information Related to Alcohol-Metabolizing Enzymes on Alcohol Reduction and Behavioral Change Among Workers: A Randomized Controlled Trial
开始日期2026-06-24 |
申办/合作机构- |
JPRN-jRCT1030250838
A quasi-experimental prospective study on the effects of exercise facility access on cognitive function
开始日期2026-03-25 |
申办/合作机构- |
ChiCTR2500115025
Evaluation of the Efficacy of Helicobacter pylori Eradication Therapy in Autoimmune Gastritis with Coexisting Infection
开始日期2025-12-31 |
申办/合作机构- |
100 项与 西妥木单抗 相关的临床结果
登录后查看更多信息
100 项与 西妥木单抗 相关的转化医学
登录后查看更多信息
100 项与 西妥木单抗 相关的专利（医药）
登录后查看更多信息
182
项与 西妥木单抗 相关的文献（医药）2026-07-01·BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
New salidroside-furoxan hybrids as potential agents inhibit triple-negative breast cancer
Article
作者: Li, Na ; Zhang, Bing ; Zhang, Siqi ; Zhang, Yongqing ; Chen, Li
Salidroside (SAL) is a natural glycoside compound with various biological activities. Recent studies have shown that SAL exhibits certain therapeutic effects on triple-negative breast cancer (TNBC). To enhance the anti-TNBC activity, 15 SAL-furoxan hybrids were designed and synthesized. The anti-proliferative activities of all target compounds against four tumor cell lines (MDA-MB-231, MCF-7, BGC-823, and A549) and a normal human cell line (MCF-10A) were evaluated using the MTT assay. A12 demonstrated the most potent inhibitory activity on MDA-MB-231 cells (IC₅₀ = 14 nM), and lower toxicity compared to DOX (SI = IC50(MCF-10A)/IC50(MDA-MB-231): 129.57 vs 1.01). Further research indicated that the anti-tumor mechanism of A12 involves the high amount of NO released in MDA-MB-231 cells and thereby induction of cells apoptosis.
2026-04-01·EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Design and evaluation of selective BET PROTACs with potent antitumor efficacy and safety against acute myeloid leukemia
Article
作者: Wei, Qingyun ; Zhou, Jinpei ; Zhang, Jian ; Zhang, Huibin ; Chen, Jiao ; Cao, Peng ; Wang, Bo ; Cai, Xueting
Targeting bromodomain and extra-terminal (BET) proteins is a promising therapeutic strategy for acute myeloid leukemia (AML). However, clinical development of conventional BET inhibitors has been limited by dose-related toxicities and compensatory resistance. Proteolysis-targeting chimeras (PROTACs) offer a catalytic and often more selective alternative by degrading target proteins via the ubiquitin-proteasome system. In this work, we designed and synthesized a series of novel BET PROTACs based on the clinical inhibitor ABBV-075. Through systematic optimization of linker length/composition and E3 ligase ligands (CRBN or VHL), we identified two highly potent PROTACs, A10 (CRBN-based) and A12 (VHL-based). Both compounds effectively degraded BET proteins, inhibited cell proliferation, induced cell-cycle arrest, and promoted apoptosis in MV4-11 AML cells. In MV4-11 xenograft models, A10 (6 mg/kg) and A12 (2 mg/kg) demonstrated significant tumor growth inhibition (76.2% and 60.5%, respectively). A comprehensive drug-likeness assessment revealed that while A12 exhibited higher systemic exposure in pharmacokinetic studies, A10 displayed a markedly superior safety profile with minimal hepatorenal toxicity. The favorable efficacy-safety balance of A10 underscores its strong potential as a preclinical candidate for AML therapy. This study highlights how rational PROTAC optimization can yield degraders with enhanced therapeutic windows, providing a promising path forward for targeted protein degradation in AML.
2026-03-26·JOURNAL OF MEDICINAL CHEMISTRY
Design and Synthesis of Pyrrolo[3,4-
d
]pyrimidine-Based ATR Degraders for Effective Treatment of Colorectal Cancer in Mouse Model
Article
作者: He, Meng-Lan ; Garrido, Carmen ; Yu, Meng-Qian ; Lirussi, Frédéric ; Hui, Zi ; Feng, Xing-Lin ; Zhou, Jia-Wei ; Wang, Chen-Chen ; Ye, Lulu ; Mao, Nian-Dong ; Du, Bo-Qun ; Ye, Guo-Wei ; Zhang, Yu-Qing ; Ye, Xiang-Yang ; Wang, Zong-Hao ; Luo, Hui ; Yao, Xia ; Li, Shun-Ran ; Gao, Yuan
Ataxia telangiectasia and Rad3-related kinase (ATR) is a pivotal DNA damage response regulator. While several ATR inhibitors have entered clinical trials, none have yet been approved for therapeutic use. A potent ATR degrader A12 based on the pyrrolo[3,4-d]pyrimidine scaffold was designed and synthesized, with the ability not only to induce proteasomal degradation of ATR (DC50: 127 nM, Dmax: 72%) but also of CHK1 (DC50: 135 nM, Dmax: 70%) in several colorectal cancer cells. It exhibits strong antiproliferative activity (IC50: 55 nM) and rapidly triggers apoptosis. In LoVo xenograft mouse model, A12 monotherapy (30 mg/kg) achieved outstanding tumor growth inhibition (TGI: 74%) without apparent toxicity. Combination with A12 (10 mg/kg) and cetuximab (3 mg/kg) further enhanced efficacy (TGI: 81%) with a favorable safety profile. These findings highlight that ATR degraders such as A12, which also degrade CHK1 simultaneously, represents as a promising therapeutic strategy for colorectal cancer and potentially other tumor types.
129
项与 西妥木单抗 相关的新闻（医药）2026-06-23
·生医讯
本文翻译自美国医药行业媒体 Firece Biotech 的一篇文章，感觉俞博士挺实在的，小编觉得这条路可行，祝信达早日达成目标，也给国内其他 biotech 作为参考
复制下面链接至浏览器或滑到最下面点“阅读原文”均可转到原文
https://www.fiercebiotech.com/biotech/5-month-sprint-behind-pfizer-10b-deal-and-innovent-global-pharma-ambition
A 5-month sprint: Behind Pfizer’s $10B deal and Innovent’s global pharma ambition
一场为期5个月的冲刺：辉瑞100亿美元交易背后与信达生物的全球制药野心
Despite its massive $10.5 billion size and 12-drug scope, Pfizer’s oncology deal with Innovent Biologics took less than five months to forge, but not without undergoing some stress tests.
尽管这笔交易规模高达105亿美元、涉及12种药物，辉瑞与信达生物的肿瘤领域合作从启动到敲定仅用了不到五个月的时间，不过这一过程也经历了一些压力测试。
The deal talks started at the J.P. Morgan Healthcare Conference in San Francisco in January this year, Innovent CEO Michael Yu, Ph.D., told Fierce Biotech.
今年1月，信达生物首席执行官俞德超博士在旧金山举行的摩根大通医疗健康会议上开启了这笔交易的谈判，他向 Fierce Biotech 透露了这一消息。
From the start, Pfizer preferred a single multi-asset deal. Hunting for a dozen different assets from separate companies—and managing those alliances later—was simply too logistically cumbersome. To Innovent, the sentiment was the same.
从一开始，辉瑞就更倾向于一笔包含多种资产的交易。从不同公司寻找十几种不同资产，再在后续管理这些合作关系，在后勤上实在太过繁琐。对于信达生物来说，想法也是一样的。
Innovent has a long history of working with multinational pharma companies (MNCs), dating back to its decade-long collaboration with Eli Lilly that began in 2015 and added its seventh chapter in February.
信达生物与跨国制药企业（MNCs）的合作历史悠久，其与礼来公司的十年合作始于2015年，并于今年2月开启了合作的第七个篇章。
“We understand what MNCs want,” Yu said. “Their motivation is to cover more projects with one company, so they don’t have to keep shopping around. We feel the exact same way.”
“我们了解跨国公司的需求，”俞说，“他们的动机是通过一家公司承接更多项目，这样就不必反复货比三家。我们的想法完全一样。”
“The effort to conduct search and evaluation, due diligence, negotiations, technology transfers and alliance management on an asset-by-asset basis is not small,” Helen Chen, global sector co-head for healthcare at L.E.K. Consulting, said in an email interview with Fierce. “Having a bundled deal with multi-asset collaborations help[s] reduce the transaction efforts. Familiarity with each other's capabilities and style reduces misunderstandings and enhances efficiency.”
“对每一项资产开展调研评估、尽职调查、谈判、技术转让以及联盟管理的工作量不小，”L.E.K. Consulting 医疗保健全球部门联合负责人 Helen Chen 在接受 Fierce 邮件采访时表示。“通过打包交易开展多资产合作，有助于减少交易工作量。双方对彼此能力和行事风格的熟悉度，能减少误解并提升效率。”
Multi-asset partnerships have become more popular between Big Pharma and large Chinese companies—even though single-program deals and platform technology research alliances remain the most common, especially among smaller biotechs. Last year, GSK also signed a 12-asset deal with China’s Hengrui Pharma, potentially worth $12 billion. And Bristol Myers Squibb followed this May with a 13-program alliance with Hengrui.
大型制药企业与中国大型企业之间的多资产合作已愈发流行——尽管单项目合作和平台技术研究联盟仍是最常见的合作形式，在小型生物技术公司中尤为如此。去年，葛兰素史克（GSK）也与中国恒瑞医药签署了一项涉及12项资产的合作协议，潜在价值达120亿美元。今年5月，百时美施贵宝（Bristol Myers Squibb）紧随其后，与恒瑞医药达成了一项13个项目的合作联盟。
These large deals were made possible in recent years thanks to an enlarged pool of molecules and improved confidence in the integrity of clinical data from China, Yu said.
俞表示，近年来，得益于中国可用于研发的分子池规模扩大以及临床数据真实性信心的提升，这些大型交易得以达成。
After the JPM conference, Pfizer sent a team to China and visited several local companies, including Innovent, according to Yu.
据俞介绍，摩根大通会议结束后，辉瑞派了一个团队前往中国，拜访了包括信达生物在内的多家本土企业。
Pfizer dug into Innovent’s drug development track record and discovery engine and was “very excited in what we saw about the quality,” Johanna Bendell, M.D., Pfizer’s chief development officer of oncology, told Fierce in a separate interview.
辉瑞肿瘤学首席开发官 Johanna Bendell 医学博士在另一次采访中告诉Fierce，辉瑞深入研究了信达生物的药物开发记录和发现引擎，“对我们看到的质量感到非常满意”。
A two-way selection process ensued. Pfizer only went for drugs that fit its portfolio, leading to its selection of altogether eight existing molecules, including one already in the clinic, four in the IND-stage, and four preclinical candidates. Innovent will also design four new molecules at the request of Pfizer, which will decide whether to take them up following clinical proof-of-concept tests performed by its Chinese partner.
一场双向筛选过程随即展开。辉瑞只挑选符合其产品组合的药物，最终共选定八种现有分子，其中包括一种已进入临床试验阶段、四种处于新药临床试验申请阶段以及四种临床前候选药物。信达生物还将应辉瑞的要求设计四种新分子，辉瑞则会在其中国合作伙伴完成概念验证临床试验后，决定是否采用这些新分子。
Co-Co or no deal 共同开发或不成交
Under the deal, Innovent negotiated a term to co-develop and co-commercialize four programs that it believes holds greater market potential based on existing information, according to Yu.
据俞介绍，根据该协议，信达生物协商了一项条款，共同开发并共同商业化四个其基于现有信息认为具有更大市场潜力的项目。
Pfizer initially resisted the co-development, co-commercialization structure, Yu recalled. Leveraging interest from other parties, Innovent threatened to walk away.
俞回忆称，辉瑞最初反对共同开发和共同商业化的架构。信达生物利用其他方的兴趣，威胁要退出合作。
At least three other potential partners were interested in a colorectal cancer multi-specific antibody candidate, Yu noted. In the U.S., colorectal cancer is the third most commonly diagnosed cancer and the second-leading cause of cancer-related death, with its rates also rising in younger adults.
俞指出，至少还有另外三家潜在合作方对一款结直肠癌多特异性抗体候选药物感兴趣。在美国，结直肠癌是第三大常见确诊癌症，也是癌症相关死亡的第二大原因，且在年轻人群中的发病率也在上升。
Underlying Innovent’s insistence was an ambition to become a global pharma company.
信达生物坚持这一点的背后，是其立志成为一家全球制药企业的雄心。
“For Chinese biopharma companies, if you only focus on the domestic market, it doesn’t matter how good you are, you’re still just second- or third-tier players,” Yu said. “Innovent is a second- or third-tier company today.”
“对于中国生物制药企业来说，如果你只盯着国内市场，不管你实力多强，也只能算是二三线玩家，”俞说。“信达生物现在就是一家二三线企业。”
Market reality determines that a company with first-tier ambition must aim for the Western market. On average, a drug would get 50% to 55% of its revenue from the U.S. and 20% to 25% from Europe, while China roughly constitutes 8% of the sales and merely 3% of the profit, Yu observed.
市场现实决定，拥有一流抱负的企业必须以西方市场为目标。俞观察到，平均而言，一款药物50%至55%的收入来自美国，20%至25%来自欧洲，而中国的销售额约占8%，利润仅占3%。
For now, Innovent’s global capabilities, including clinical development, regulatory affairs and manufacturing, are not robust enough to get a novel drug across the FDA by itself, the CEO acknowledged.
信达生物的首席执行官承认，目前公司在临床开发、注册事务和生产制造等方面的全球能力还不够强大，无法仅凭自身将一款新药通过美国食品药品监督管理局（FDA）的审批。
On the commercial side, Innovent is no better than a biotech startup when it comes to reimbursement negotiations, placement on hospitals’ drug formularies, medical affairs, as well as distribution and marketing pathways in the U.S., he added.
他补充道，在商业层面，就报销谈判、医院药品目录准入、医学事务以及美国的分销和营销渠道而言，信达生物在这些方面并不比一家生物科技初创公司更有优势。
“That’s why we have to find a company that is willing to take this journey together with us,” Yu said.
“这就是为什么我们必须找到一家愿意与我们一起踏上这段旅程的公司，”俞说。
That was the same reason why Innovent pursued a co-development and co-commercialization deal structure with Takeda on a potential first-in-class PD-1/IL-2 bispecific antibody fusion protein called IBI363 (TAK-928).
这也是信达生物与武田就一款潜在的全球首创 PD‑1/IL‑2 双特异性抗体融合蛋白 IBI363 (TAK-928) 采用联合开发与联合商业化合作模式的原因。
A global 2030 plan 2030年全球计划
IBI363 is being tested in a global phase 3 trial in PD-(L)1-pretreated squamous non-small cell lung cancer, with a second phase 3 being planned in nonsquamous histology.
IBI363 正在一项针对 PD-(L)1 经治鳞状非小细胞肺癌的全球 III 期临床试验中接受测试，第二项针对非鳞状组织学类型的 III 期试验正在规划中。
The drug is among three of Innovent-developed assets that either entered or are ready to start global phase 3 trials, alongside a Claudin 18.2 ADC also included in the Takeda deal and a VEGFxAng2 bispecific that’s been partnered with newly formed eye disease specialist Ollin Biosciences.
这款药物是信达生物自主研发的三项资产之一，这三项资产均已进入或准备启动全球III期临床试验；另外两项资产分别是与武田制药合作协议中包含的一款Claudin 18.2抗体药物偶联物，以及一款已与新成立的眼科疾病专业企业Ollin Biosciences达成合作的VEGFxAng2双特异性抗体。
Innovent’s publicly disclosed goal is to grow that number to at least five assets by 2030, while the company has set more detailed internal targets, including the percentage of global sales in its overall revenues, Yu said.
俞表示，信达生物公开披露的目标是到2030年将这一数量至少增至5个产品，而该公司还制定了更具体的内部目标，包括全球销售额在其总收入中所占的比例。
The deals Innovent has signed so far “not only bring substantial financial returns to the company, but more importantly, integrate global resources to accelerate the realization of our pipeline's value and help us build the core capabilities needed for our journey to becoming a truly global biopharmaceutical company,” Yu said during Innovent’s 2025 full-year earnings call in March.
俞在今年3月信达生物2025年全年业绩电话会上表示：“信达生物迄今为止签署的合作协议，不仅为公司带来了可观的财务回报，更重要的是整合全球资源，加速我们研发管线价值的兑现，助力我们打造成为真正的全球生物制药企业所需的核心能力。”
“We are confident to propose our Vision 2030: evolving from a leading biopharmaceutical company in China into a global premier biopharmaceutical company,” he said.
“我们有信心提出我们的2030愿景：从中国领先的生物制药企业发展成为全球顶尖的生物制药企业，”他说。
Eventually, Innovent could find a niche product with a limited number of physicians involved to try launching alone in the U.S., Yu said.
俞表示，最终信达生物可以找到一款小众产品，参与的医生数量有限，从而尝试在美国自主推出该产品。
After signing the massive Pfizer deal, Innovent is taking a break from oncology business development to focus on the ones already underway, including those with Roche, Yu said. But the company remains open to striking deals in other disease areas.
俞表示，在与辉瑞达成这笔大额交易后，信达生物暂时暂停了肿瘤领域的业务拓展，转而聚焦于已在推进的项目，包括与罗氏合作的项目。不过，该公司仍愿意在其他疾病领域达成合作协议。
Innovent’s portfolio currently spreads across four large therapeutic areas: oncology, cardiovascular and metabolic disease, immunology and ophthalmology.
信达生物的产品管线目前覆盖四大核心治疗领域：肿瘤、心血管与代谢疾病、免疫学及眼科疾病。
To Yu, becoming a global pharma also means narrowing down. Admiring how disciplined Big Pharma companies are in their selection of focus areas, Yu suggested that Innovent’s pipeline is too broad for a company of its size.
对于信达生物而言，成为一家全球性制药企业也意味着聚焦。信达生物欣赏大型制药公司在选择核心领域时的严谨态度，因此认为以其目前的规模，创新生物的研发管线过于宽泛。
He raised the example of oncology. While there are about 2,000 tumor types, pharma companies typically only focus on three to four cancers, he said.
他举了肿瘤学的例子。他表示，虽然肿瘤类型约有2000种，但制药公司通常只关注三到四种癌症。
“We ought to cut 50% of [disease areas] in the future,” Yu said. “We should be more focused.”
“我们未来应该砍掉50%的[疾病领域]，”俞说。“我们应该更专注。”
2026-06-21
·医脉通
来源 | 医脉通减重智库
引言：减肥并长期维持体重往往让人感觉像是一项“不可能的任务”：面对琳琅满目的深加工食品和无孔不入的营销广告，我们的大脑常被高度诱人的味道俘获，导致食欲系统过载，自我调节进食变得异常艰难。为了瘦下来，许多人陷入了复杂的计算——每日卡路里目标、精心设计的“欺骗餐”、为了一顿大餐而刻意“省下”额度……然而，这种过度严苛的制度化管理，反而让简单的减重目标愈发沉重且难以坚持。那么，是否存在一种更简单、更具可持续性的方法？
发表在《健康心理学》杂志上的一项最新研究为我们提供了一个全新视角：通过建立“重复进食”的习惯，或许能让减重过程变得更加轻松且高效。
为什么吃得越单调瘦得越快？
点击下图了解详情
科学实验：重复进食如何影响体重？
为了探索重复饮食习惯与减重成功之间的关系，研究人员开展了一项为期12周的实验。之所以选择12周，是因为这一周期足以观察到具有临床意义的体重变化，同时也是参与者对食物记录等行为保持高度依从性的“黄金窗口期”。
实验共邀请了112名成年人，他们被要求使用Fitbit等工具记录饮食并监测体重变化。研究人员重点考察了两个核心指标：
热量稳定性：衡量每日摄入的热量波动情况，包括日常变化以及工作日与周末之间的差异。
饮食重复率：衡量饮食的多样程度，即在记录中，重复出现超过10次的食物所占的比例。
参与者被随机分配到两个组：标准组接受每周一次的常规行为减重指导；优化组则接受更具针对性的干预，根据参与者的反馈调整支持方式。
值得注意的是，这项研究并不强制要求参与者遵循特定的食谱或严格限制卡路里数值，而是观察他们自发形成的进食模式与减重效果之间的关联。
惊人发现：吃得越“单调”的人瘦得越多
研究结果显示，饮食的重复程度与减重效果之间存在显著的正相关关系。
1. 重复率的优势：数据显示，那些在饮食中展现出更高重复性的参与者，其减重效果明显更好。具体而言，如果一个人的食物记录中，重复项占比超过50%，其平均减重比例可达起始体重的5.9%；相比之下，饮食结构更为多样化（重复率较低）的人，平均减重比例仅为4.3%。
2. 决策疲劳的心理陷阱：为什么“吃得单调”反而更有效？研究者认为，这并非因为重复的食物本身有某种神奇魔力，而是因为它简化了决策过程。 在充满诱惑的环境中，每做一次“吃什么”的决定都会消耗心理能量。通过重复正餐和零食，可以显著减少餐饮规划的心理负担，从而降低“决策疲劳”。当进食行为变成一种习惯性的、无需思考的过程时，人们对减重计划的依从性就会显著提高。
意外的发现：周末的“灵活性”
在考察“热量稳定性”时，研究人员发现了一个有些出人意料的结果。
通常我们认为，每天摄入相同的热量最有利于维持体重。然而研究发现，那些在周末摄入热量略高于工作日的参与者，实际上减掉的体重更多。
这与传统的“每日严控”观念背后的逻辑有所不同。研究人员推测，一种更为灵活的饮食模式——允许周末适度多吃——可能有助于缓解长期饮食控制带来的“匮乏感”。这种心理上的缓冲，反而让人们在漫长的一周里更容易坚持健康的饮食习惯，从而在整体上实现了更好的依从性。
实践指南：如何建立你的“基础食谱”？
虽然研究强调了重复的力量，但这并不意味着你余生只能吃同样的几种食物。食物不仅是卡路里的组合，还承载着文化、社交和享受。一个过于僵化、追求“完美”的方案是很难长久维持的。
最有效的策略是：建立一个“可重复的饮食基础”，同时保留一定的灵活性。
以下是几个简单的实践建议：
构建“基础餐单”：找出几款你真心喜欢且营养均衡的早餐、午餐或零食方案，将它们作为你每周的常备选择。通过减少日常决策的数量，你会发现坚持下去变得不再那么依赖意志力。
利用“结构化替换”：当你对某款基础餐食感到厌倦时，不要推倒重来。尝试保持餐食的基础结构不变，仅替换其中的部分食材。例如，基础框架是“蛋白质+谷物+蔬菜”，你可以将鸡肉换成鱼肉，将糙米换成藜麦，这样既能维持多样性，又不会增加决策负担。
提前规划：无论是固定的每周购物清单，还是专门抽出一个下午进行“预制餐”（Meal Prepping），提前规划都能有效减少临阵磨枪时的不健康选择。
接纳不完美：避开极端和僵化的思维。一个可持续的减重方案应该是能够融入生活的。建立起重复进食的根基，同时在社交或庆祝场合留出享受的空间，这种平衡才是习惯长久持续的关键。
结语
减重的核心往往不在于你掌握了多少深奥的营养学知识，而在于你能否将健康的行为内化为一种轻松的习惯。这项发表在《健康心理学》上的研究提醒我们：在充满选择的世界里，“精简”就是力量。通过建立重复的饮食模式，我们可以把有限的意志力从繁杂的食物决策中解放出来，从而更稳健地走向理想的健康目标。记住，最有效的策略，永远是那个你能坚持最久的策略。
参考文献
[1]Hall KD. Did the food environment cause the obesity epidemic?. Obesity (Silver Spring). 2018;26(1):11-13. doi:10.1002/oby.22073
[2]Kirk SF, Penney TL, McHugh TL. Characterizing the obesogenic environment: the state of the evidence with directions for future research. Obes Rev. 2010;11(2):109-117. doi:10.1111/j.1467-789X.2009.00611.x
[3]LaFata EM, Gearhardt AN. Ultra-processed food addiction: An epidemic? Psychother Psychosom. 2022;91(6):363-372. doi:10.1159/000527322.
[4]Brown MD, Lackey, HD, Miller TK, Priest D. Controlling Calories—The Simple Approach. Diabetes Spectr. 2001;14(2):110–112. https://doi.org/10.2337/diaspect.14.2.110
[5]Murray SB, Pila E, Mond JM, et al. Cheat meals: A benign or ominous variant of binge eating behavior?. Appetite. 2018;130:274-278. doi:10.1016/j.appet.2018.08.026
[6]Hagerman CJ, Hong AE, Crane NT, Butryn ML, Forman EM. Do routinized eating behaviors support weight loss? An examination of food logs from behavioral weight loss participants. Health Psych. 2026. https://doi.org/10.1037/hea0001591.
[7]Ross KM, Qiu P, You L, Wing RR. Characterizing the pattern of weight loss and regain in adults enrolled in a 12-week internet-based weight management program. Obesity (Silver Spring). 2018;26(2):318-323. doi:10.1002/oby.22083
[8]Crane N, Hagerman C, Horgan O, Butryn M. Patterns and predictors of engagement with digital self-monitoring during the maintenance phase of a behavioral weight loss program: Quantitative study. JMIR Mhealth Uhealth. 2023;11:e45057. doi:10.2196/45057
[9]Goldstein SP, Goldstein CM, Bond DS, Raynor HA, Wing RR, Thomas JG. Associations between self-monitoring and weight change in behavioral weight loss interventions. Health Psychol. 2019;38(12):1128-1136. doi:10.1037/hea0000800
[10]Hill C, Weir BW, Fuentes LW, Garcia-Alvarez A, Anouti DP, Cheskin LJ. Relationship between weekly patterns of caloric intake and reported weight loss outcomes: Retrospective cohort study. JMIR Mhealth Uhealth. 2018;6(4):e83. doi:10.2196/mhealth.8320[11]Lally P, Gardner B. Promoting habit formation. Health Psych Rev. 2013;7(Suppl 1):S137–S158.https://doi.org/10.1080/17437199.2011.603640.
责编｜Zelda
封面图来源｜视觉中国
重磅！2025年影响因子新鲜出炉：CA再创新高，国产期刊强势崛起
签了知情同意书也没用？贵州高院这份指引，每个医生都应该看看丨医眼看法
医脉通是专业的在线医生平台，“感知世界医学脉搏，助力中国临床决策”是平台的使命。医脉通旗下拥有「MedSeeker」「临床指南」「用药参考」「医学文献王」「医知源」「e研通」「e脉播」等系列产品，全面满足医学工作者临床决策、获取新知及提升科研效率等方面的需求。
☟戳这里，更有料！
2026-06-18
·研日新
日报精选医学文献
今日精选20篇医学文献，查看更多请点击阅读原文
本文支持继续浏览摘要内容；完整摘要、收藏文章、订阅管理等完整功能，请前往小程序「医研日新」。前往小程序查看更多与订阅收藏
1. Single-cell multi-omics dissection of RevitalAge Markers uncovers age-dependent immunotherapy resistance and druggable targets in melanoma. [Melanoma]
Biology direct | 2026-06-17 | IF 5.7
AIST3GAL4可作为老年黑色素瘤患者免疫治疗耐药的预测标志物和潜在治疗靶点，联合RAF/MEK抑制剂具有应用前景。
摘要Aging-related molecular reprogramming profoundly influences melanoma progression and therapeutic sensitivity, yet underlying mechanisms remain poorly understood. We constructed a comprehensive multi-omics atlas integrating mutations, transcription, methylation, and copy number variations, utilizing the MOFA algorithm to uncover key age-driving factors. Among 20 factors, Factor6 exhibited significa...查看完整摘要
2. Breaking the mast cell-T helper 2 axis in atopic dermatitis: Insights from oral MRGPRX2 antagonist. [Dermatitis]
The Journal of investigative dermatology | 2026-06-17 | IF 5.7
AIMRGPRX2拮抗剂通过双重机制（抑制肥大细胞活化+阻断Th2轴）为难治性特应性皮炎提供精准靶向治疗新选择。
3. Bintrafusp alfa for patients with recurrent or metastatic olfactory neuroblastoma. [Skin Diseases]
Cancer immunology, immunotherapy : CII | 2026-06-17 | IF 5.1
AIBintrafusp alfa在R/M ONB中虽未达客观缓解终点，但展现可控安全性及部分患者的持久获益，证实了该罕见肿瘤免疫治疗临床试验的可行性。
摘要There is no established treatment for patients with recurrent/metastatic (R/M) olfactory neuroblastoma (ONB), a rare sinonasal tumor. We conducted the first immunotherapy clinical trial (NCT05012098) in patients with R/M ONB, to evaluate the activity of the bifunctional TGF-β "trap"/anti-PD-L1 fusion protein bintrafusp alfa (BA).
Patients received BA (1200 mg, intravenously) every 2 weeks. Primary...查看完整摘要
4. Programmable mRNA 3'UTR engineering restores MHC-I and overcomes immune evasion in prostate cancer. [Melanoma]
Nature biomedical engineering | 2026-06-16 | IF 26.8
AI该研究为克服前列腺癌免疫治疗耐药提供了新靶点，通过LNP递送的3'UTRCES平台精准恢复MHC-I表达，有望将免疫冷肿瘤转化为热肿瘤，提升ICT疗效。
摘要Immune-cold tumours such as prostate cancer often resist immune checkpoint therapies (ICT) due to impaired antigen presentation via major histocompatibility complex class I (MHC-I). While MHC-I downregulation is a common immune evasion mechanism, no approved therapies selectively restore MHC-I expression in tumours. We developed a programmable RNA engineering platform, termed the 3'UTR CRISPR/dCas...查看完整摘要
5. Clinical utility of immune biomarker staining of skin biopsies in psoriasis and eczematous dermatitis: A single-center retrospective analysis. [Psoriasis]
Journal of the American Academy of Dermatology | 2026-06-16 | IF 12.8
AI免疫生物标志物染色可作为银屑病与湿疹性皮炎鉴别诊断的有效辅助工具，尤其对组织形态学重叠的疑难病例具有重要的临床参考价值。
6. AKAP1 enhances glycogen accumulation and hepatocarcinogenesis through YTHDF2-mediated G6PC mRNA decay. [Carcinoma, Hepatocellular]
Signal transduction and targeted therapy | 2026-06-16 | IF 40.8
AIAP-21肽抑制剂通过靶向AKAP1线粒体定位可有效抑制糖原积累和肝癌发生，为HCC提供了一种新颖且无明显毒性的治疗策略。
摘要During recent years, a growing body of evidence has revealed that metabolic rewiring of glycogen is a hallmark of cancer that plays a significant role in tumor development and progression. Nonetheless, the molecular mechanism underlying the dysregulation of glycogen remains largely unknown. In this study, using liver-specific AKAP1 depletion and overexpression mouse models, we demonstrated that AK...查看完整摘要
7. Valorization of Sea Buckthorn (Hippophae rhamnocaides L.) Leaves: Polyphenol-Rich Extract Targeting Helicobacter pylori Virulence and Gastric Mucosal Homeostasis. [Helicobacter Infections]
Journal of agricultural and food chemistry | 2026-06-05 | IF 5.7
AI沙棘叶提取物对多重耐药幽门螺杆菌具有显著抑制作用，并兼具黏膜保护功效，可作为传统抗生素疗法外的一种天然辅助治疗选择。
摘要Sea buckthorn (Hippophae rhamnoides L.) leaves are rich in polyphenols and exhibit potent activity against Helicobacter pylori. This study found that its extract demonstrates a dual mechanism of action, inhibiting bacterial virulence while protecting the gastric mucosa. For multidrug-resistant strains, the minimum inhibitory concentration (MIC) range of this extract was 0.08-0.64 mg/...查看完整摘要
8. Patient-derived organoids from metastatic colorectal cancer mirror tumor heterogeneity and predict patient survival and drug sensitivity. [Liver Neoplasms]
Cell reports. Medicine | 2026-05-28 | IF 11.7
AI类器官形态学特征可快速预测转移性结直肠癌药物敏感性，囊性形态提示更高化疗敏感性，为个性化治疗决策提供实时体外药敏参考。
摘要This study reports the pharmacogenomic analysis of tumor heterogeneity in a living biobank of 213 organoids derived from liver metastases of 102 patients with metastatic colorectal cancer. Successful organoid establishment reflects poorer chemosensitivity and patient survival. Molecular fidelity is confirmed in tumor-organoid pairs, and multi-modal phenotypes are defined based on organoid morpholo...查看完整摘要
9. Leveraging longitudinal data to boost statistical power for gene-environment interaction analysis. [Mental Disorders]
Nature computational science | 2026-06-16 | IF 12.0
AISAGELD方法通过高效利用纵向随访数据显著提升基因-环境交互分析的统计效能，可帮助临床识别更多疾病风险基因位点，为个体化预防策略提供遗传学依据。
摘要Gene-environment interaction (G×E) analyses play a crucial role in advancing genetic discovery, addressing missing heritability, and facilitating precision medicine. However, existing G×E methods are mostly designed for cross-sectional data, limiting the utility of longitudinal data. Here we propose SAGELD, a scalable and accurate genome-wide G×E method for longitudinal traits that controls for sa...查看完整摘要
10. Digital Tools to Support Mental Health in Later Life: Scoping Review of Systematic Reviews. [Mental Disorders]
综述 | Current psychiatry reports | 2026-06-16 | IF 6.7
AI数字工具在改善老年人抑郁症状方面具有一定潜力，但当前证据质量参差不齐，临床应用时需关注工具的可用性评估及长期有效性验证。
摘要This scoping review synthesises existing evidence from systematic reviews on the effectiveness and implementation of digital mental health interventions among community-dwelling older adults.
Twenty-one systematic reviews were included. Results showed that a range of digital tools demonstrate potential to improve common mental health and psychosocial symptoms among older adults, with most evidence...查看完整摘要
11. The Joy and the Pain of Being Alone: Managing the Solitude-Loneliness (SOLO) Paradox in People High on the Autism Spectrum. [Autism Spectrum Disorder]
综述 | Clinical child and family psychology review | 2026-06-16 | IF 6.1
AI自闭症患者的孤独感与独处偏好可同时存在且相互矛盾，临床干预需平衡其社交需求与独处偏好，而非简单鼓励社交接触。
摘要This narrative review examines the complex relationship between autism and two fundamental social needs: the need to belong and the need to be alone, which underpin the conceptually distinct experiences of loneliness and solitude. After outlining core features of autism spectrum disorder-focusing on characteristic patterns of social functioning across the spectrum-we synthesize evidence showing th...查看完整摘要
12. Distinct contributions of schizophrenia and neurotransmitter pathway genetic liability to neurocognition and antipsychotic efficacy in drug-naïve first-episode schizophrenia. [Schizophrenia]
Molecular psychiatry | 2026-06-15 | IF 9.6
AIGABA和5-HT通路多基因风险评分可预测抗精神病药疗效，有望成为指导个体化用药的潜在生物标志物。
摘要The genetic mechanisms underlying heterogeneity in symptom presentation and antipsychotic response in schizophrenia remain unclear, limiting the development of personalized treatment. We integrated genome-wide schizophrenia polygenic risk scores (SZ-PRS) and pathway-specific PRSs (pPRSs) for four major neurotransmitter systems to examine their associations with clinical phenotypes across the cours...查看完整摘要
13. A novel composite model of PTSD induced by social bullying: validation via multidimensional behavioral and molecular biomarkers. [Mental Disorders]
Molecular psychiatry | 2026-06-15 | IF 9.6
AI新型社会欺凌模型填补了社会创伤相关PTSD动物模型的空白，社交回避表型可指导临床识别高危个体，氟西汀的疗效验证为此类患者提供治疗参考。
摘要Post-traumatic stress disorder (PTSD) is a debilitating psychiatric condition characterized by persistent fear memory, hyperarousal, and social impairment. Mounting evidence highlights the critical role of social stress, such as bullying, in triggering PTSD. However, progress in elucidating the underlying mechanisms and developing effective treatments has been hindered by the lack of animal models...查看完整摘要
14. Alterations in Cardiac and Systemic Metabolism in Heart Failure. [Heart Failure]
综述 | Circulation. Heart failure | 2026-06-17 | IF 7.8
AIHFrEF与HFpEF存在截然不同的代谢异常模式，针对代谢通路的新疗法（SGLT-2i、GLP-1RA）可能通过纠正代谢紊乱改善患者预后。
摘要Altered cardiac and systemic metabolism is a hallmark of heart failure (HF). In the failing heart, cardiomyocytes develop alterations in substrate preference, mitochondrial oxidative metabolism, and the shuttling of high-energy phosphates from mitochondria to the cytosol that compromise energetic efficiency and contribute to disease progression. At the systemic level, neurohormonal activation play...查看完整摘要
15. The microbiome in reptile health, disease, and ecology. [Zoonoses]
综述 | Microbiology and molecular biology reviews : MMBR | 2026-06-17 | IF 7.8
AI爬行动物微生物组研究揭示了外热性动物独特的宿主-微生物互作模式，为理解脊椎动物微生物组多样性及珍稀物种保护提供重要参考。
摘要SUMMARYReptiles are a diverse and speciose class of animals that are broadly threatened by habitat loss, climate change, and other factors. From a microbiological perspective, reptiles have historically been examined as a source of disease, particularly salmonellosis, with most studies being culture-based investigations into causative agents of disease and potential for zoonoses. More recent work ...查看完整摘要
16. Application of hydrogel technologies in the treatment of musculoskeletal disorders. [Osteoarthritis]
Chinese medical journal | 2026-06-17 | IF 7.5
AI水凝胶技术为骨关节炎、软骨损伤等常见MSDs提供了有前景的非手术再生治疗策略，但临床转化仍需解决机械耐久性、生物活性可控释放及规模化生产等关键挑战。
摘要Musculoskeletal disorders (MSDs) represent a diverse group of conditions affecting bones, cartilage, intervertebral discs, tendons, muscles, and related structures, and continue to be a leading cause of global disability. Despite advancements in surgery and pharmacotherapy, issues such as incomplete regeneration, limited longevity, and procedure-related complications remain unresolved. As a result...查看完整摘要
17. Tenecteplase Beyond the 4.5-h Window for Patients with Acute Ischemic Stroke: An Updated Meta-Analysis of Randomized Controlled Trials. [Hemorrhage]
系统综述 | CNS drugs | 2026-06-17 | IF 7.4
AI对于发病超过4.5小时的急性缺血性卒中患者，替奈普酶可显著改善功能预后，虽症状性颅内出血风险略增，但绝对值低，可作为经筛选患者的有效溶栓选择。
摘要Intravenous thrombolysis (IVT) is the established treatment for acute ischemic stroke (AIS) when administered within 4.5 h of the last known well (LKW) status. However, this narrow therapeutic window limits the number of patients eligible for treatment. In this context, tenecteplase (TNK) is being investigated as an alternative thrombolytic agent in the extended time window.
The objective of this ...查看完整摘要
18. An injectable SFMA/HA-E hydrogel for sustained delivery of hucMSC-derived exosomes promotes myocardial repair after infarction. [Heart Failure]
Stem cell research & therapy | 2026-06-17 | IF 7.1
AI可注射水凝胶缓释人脐带间充质干细胞外泌体可实现单次给药显著改善心功能，为心肌梗死患者提供一种微创、高效的细胞衍生生物疗法新选择。
摘要Myocardial infarction (MI) causes permanent loss of cardiomyocytes and heart failure. Human umbilical cord mesenchymal stem cell-derived exosomes (hucMSCs-Exos) have shown therapeutic potential. Still, their clinical utility is limited by rapid systemic clearance, highlighting the need for a delivery system to achieve sustained release and effect.
We fabricated an injectable, photopolymerizable hy...查看完整摘要
19. Long-term metabolically unhealthy aging, its underlying molecular underpinnings, and association with cognitive impairment: a 12.4-year longitudinal cohort study. [Hypertension]
BMC medicine | 2026-06-17 | IF 7.0
AI代谢不健康衰老与认知功能下降和脑结构萎缩密切相关，通过监测代谢指标和特定生物标志物可早期识别高危人群，为延缓认知衰退提供干预窗口。
摘要Individuals experience heterogeneous aging processes closely associated with metabolism. However, it remains unclear whether older adults undergo different metabolic health-related aging patterns over time. We aimed to investigate the long-term metabolic health-related aging trajectories, their associations with cognitive function, and underlying molecular underpinnings among older adults.
This st...查看完整摘要
20. Retinal Vascular Caliber: 6 to 12 Months and 15 to 25 Years Following Hypertensive Pregnancy. [Hypertension]
Hypertension (Dallas, Tex. : 1979) | 2026-06-17 | IF 6.9
AI子痫前期女性产后存在持续的视网膜血管异常，这一发现提示临床医生应对此类患者进行长期心血管风险监测。
摘要Women display retinal vessel caliber abnormalities after hypertensive pregnancy, but whether these predate or reflect vascular aging is unknown.
Retinal imaging was performed in 2 cohorts: 196 women at 6 to 12 months postpartum (167 hypertensive, 29 normotensive), and 105 women at 15 to 25 years postpartum (64 hypertensive, 41 normotensive), using identical imaging/analysis protocols (Imedos Healt...查看完整摘要
在小程序获取完整功能
收藏文章、管理订阅、查看本期完整摘要与个性化内容，请前往小程序「医研日新」。
前往小程序查看更多内容
免责声明：仅供学术交流参考，不构成任何医学建议或诊疗指导
100 项与 西妥木单抗 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 肺泡软组织肉瘤 | 临床2期 | 美国 | 2012-06-18 | |
| 肺泡软组织肉瘤 | 临床2期 | 加拿大 | 2012-06-18 | |
| 尤文肉瘤 | 临床2期 | 美国 | 2012-06-18 | |
| 尤文肉瘤 | 临床2期 | 加拿大 | 2012-06-18 | |
| 神经胶质肉瘤 | 临床2期 | 美国 | 2012-06-18 | |
| 神经胶质肉瘤 | 临床2期 | 加拿大 | 2012-06-18 | |
| 血管肉瘤 | 临床2期 | 美国 | 2012-06-18 | |
| 血管肉瘤 | 临床2期 | 加拿大 | 2012-06-18 | |
| 脂肪肉瘤 | 临床2期 | 美国 | 2012-06-18 | |
| 脂肪肉瘤 | 临床2期 | 加拿大 | 2012-06-18 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
临床2期 | 18 | 遞餘衊齋鹽淵遞鬱積糧(糧廠窪網鬱鏇艱網壓願) = 蓋齋積願鏇衊齋遞蓋簾 膚製遞鏇壓夢積簾壓醖 (觸築鹽鏇遞鬱糧襯鏇選 ) 更多 | 不佳 | 2020-12-01 | |||
临床1期 | 16 | (cohort 1) | 觸襯鹽鏇糧淵鹽鏇衊艱(淵鑰餘繭淵積齋製餘糧) = The most common adverse events included hyperglycemia (100%; 31% grade 3), oral mucositis (63%; 19% grade 3), and diarrhea (44%; 0 grade 3). Low-grade pneumonitis occurred in 7 of 11 patients (44%; 0 grade 3). 鹹網襯艱獵遞鑰艱蓋襯 (糧範觸鏇築鹹憲願網簾 ) 更多 | 不佳 | 2020-06-01 | ||
(cohort -1) | |||||||
临床2期 | 16 | (Cetuximab) | 網選鏇範鏇艱廠築製築 = 鏇構夢衊構築遞蓋願觸 選簾衊簾壓製衊顧蓋餘 (願繭齋製網憲觸鏇醖襯, 範觸壓繭遞襯夢願艱醖 ~ 餘網構觸選糧簾網鹽窪) 更多 | - | 2020-03-19 | ||
(IMC-A12) | 網選鏇範鏇艱廠築製築 = 膚鹽願繭齋鹽襯積壓願 選簾衊簾壓製衊顧蓋餘 (願繭齋製網憲觸鏇醖襯, 積積遞襯遞範遞網壓鹽 ~ 淵獵壓繭夢製獵壓簾繭) 更多 | ||||||
临床2期 | 210 | Androgen deprivation + cixutumumab | 襯糧鹽網廠製餘膚齋積(觸膚齋遞蓋獵鏇鏇鏇鑰): HR = 1.01 (95% CI, 0.7 ~ 1.45), P-Value = 0.97 更多 | 不佳 | 2020-02-19 | ||
Androgen deprivation | |||||||
临床1/2期 | 16 | (IMC-A12: 6 mg/kg Temsirolimus 20 mg) | 觸願壓繭膚鬱壓衊觸衊 = 製範膚醖遞遞鹹簾夢餘 膚淵鏇簾糧淵觸選壓憲 (願構積廠廠觸觸遞窪築, 襯夢壓醖選構積範築獵 ~ 糧獵齋鬱鬱糧鏇鹽網顧) 更多 | - | 2019-06-17 | ||
(IMC-A12: 6 mg/kg Temsirolimus 25 mg) | 觸願壓繭膚鬱壓衊觸衊 = 壓繭蓋遞構製齋積糧齋 膚淵鏇簾糧淵觸選壓憲 (願構積廠廠觸觸遞窪築, 齋觸鹽夢繭壓顧夢積醖 ~ 鬱鏇顧範淵憲範鏇願鑰) 更多 | ||||||
临床2期 | 64 | Carboplatin+Pemetrexed (Carboplatin + Pemetrexed x 4 Cycles Followed by Maintenance Pe) | 鬱鏇構壓醖鹹齋膚願糧(鏇鹽夢鬱獵壓衊窪獵憲) = 衊遞觸構齋餘齋製簾壓 鏇選壓範糧壓鑰齋網簾 (鑰築糧壓憲壓觸糧積鏇, 遞廠衊糧觸觸糧簾鏇鹽 ~ 鹹簾繭鬱窪廠網築鹽繭) 更多 | - | 2019-05-08 | ||
(Carboplatin + Pemetrexed + Bevacizumab Followed by Maintenance) | 鬱鏇構壓醖鹹齋膚願糧(鏇鹽夢鬱獵壓衊窪獵憲) = 簾膚鏇夢壓夢夢簾鹹網 鏇選壓範糧壓鑰齋網簾 (鑰築糧壓憲壓觸糧積鏇, 積齋構鹽鬱膚觸範鹽憲 ~ 選積繭鏇築遞構獵顧鬱) 更多 | ||||||
临床1期 | 21 | (Cixutumumab Cohort 1) | 齋襯顧積繭鏇選膚艱醖 = 鏇積鏇積鹽鑰網積夢積 遞遞鬱窪窪衊鏇鹹繭夢 (艱鹹築構獵糧鏇鹽願繭, 襯艱憲衊構蓋醖範網鏇 ~ 鬱襯簾齋衊廠廠蓋衊鬱) 更多 | - | 2019-02-27 | ||
(Cixutumumab Cohort 2) | 齋襯顧積繭鏇選膚艱醖 = 壓淵獵窪窪積鹽壓蓋築 遞遞鬱窪窪衊鏇鹹繭夢 (艱鹹築構獵糧鏇鹽願繭, 構鬱醖遞憲鏇選鹹衊製 ~ 鑰鏇蓋願積鹹製齋鬱鏇) 更多 | ||||||
临床1期 | 24 | (3 mg/kg) | 選繭艱鏇淵膚鏇廠鹹顧 = 餘窪餘鑰構鑰網餘餘壓 鏇淵齋憲鬱壓醖餘範醖 (繭顧蓋範願觸糧網壓醖, 獵廠醖簾構範製壓壓餘 ~ 蓋鹹獵築壓鏇鏇構鑰築) 更多 | - | 2018-10-22 | ||
(6 mg/kg) | 選繭艱鏇淵膚鏇廠鹹顧 = 獵獵糧艱廠淵鑰選簾繭 鏇淵齋憲鬱壓醖餘範醖 (繭顧蓋範願觸糧網壓醖, 遞窪觸遞廠憲簾壓簾築 ~ 廠鹽繭齋獵鹽繭蓋製選) 更多 | ||||||
临床2期 | 41 | (Cixutumumab 10 mg/kg) | 襯網廠膚簾簾鹽鹽積獵(膚築構觸觸顧淵淵繭窪) = 網願鑰範鏇範鹹餘淵構 繭淵鬱壓選製憲艱顧範 (醖鏇鏇艱製網醖醖範鏇, 壓襯鏇網鹽艱襯網鬱廠 ~ 窪鏇製蓋鑰範鹹構製顧) 更多 | - | 2018-07-19 | ||
(Cixutumumab 20 mg/kg) | 襯網廠膚簾簾鹽鹽積獵(膚築構觸觸顧淵淵繭窪) = 鑰願夢壓選衊壓網齋齋 繭淵鬱壓選製憲艱顧範 (醖鏇鏇艱製網醖醖範鏇, 獵憲廠廠鏇積蓋鏇鏇觸 ~ 鹽憲構築衊衊夢築艱膚) 更多 | ||||||
临床2期 | 113 | (Ewing's Sarcoma/PNET) | 糧網襯獵願襯鏇壓構願 = 淵糧選選鬱獵糧積鹹衊 簾網憲鏇繭積艱觸餘窪 (範夢範衊艱獵窪餘膚顧, 淵範範鑰糧淵糧窪齋鏇 ~ 餘壓築襯醖糧範憲鑰鏇) 更多 | - | 2018-07-17 | ||
(Rhabdomyosarcoma) | 糧網襯獵願襯鏇壓構願 = 遞窪積築鹹糧憲顧夢觸 簾網憲鏇繭積艱觸餘窪 (範夢範衊艱獵窪餘膚顧, 鬱艱齋糧膚壓簾製蓋齋 ~ 構繭餘醖齋鬱壓觸願醖) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用